Pharmacological principles of intraperitoneal and bidirectional chemotherapy
Pleura and Peritoneum · 27.06.2017 · 2 (2) · 47-62
DOI: 10.1515/pp-2017-0010 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pleura and Peritoneum, online erschienen am 29.04.2017. Verfasst von Eelco de Bree und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgical Oncology, Medical School of Crete University Hospital, Heraklion, Greece. Die Arbeit wurde bisher 106-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Intraperitoneal chemotherapy is associated with a significant pharmacokinetic and pharmacodynamic benefit and can, alone or in combination with systemic chemotherapy (bidirectional chemotherapy), be used for treating primary and secondary peritoneal surface malignancies. Due to the peritoneal–plasma barrier, high intraperitoneal drug concentration can be achieved by intraperitoneal chemotherapy, whereas systemic concentration remains low. Bidirectional chemotherapy may provide in addition adequate drug concentrations from the side of the subperitoneal space to the peritoneal tumour nodules. Major pharmacological problems of intraperitoneal chemotherapy are limited tissue penetration and poor homogeneity of drug distribution to the entire seroperitoneal surface. Significant pharmacological determinants of intraperitoneal chemotherapy are choice of drug, drug dosage, solution volume, carrier solution, intra-abdominal pressure, temperature, duration, mode of administration, extent of peritonectomy and interindividual variability. Drugs most commonly applied for intraperitoneal chemotherapy include mitomycin C, cisplatin, carboplatin, oxaliplatin, irinotecan, 5-fluoruracil, gemcitabine, paclitaxel, docetaxel, doxorubicin, premetrexed and melphalan. The drugs and their doses that are used vary widely among centres. While the adequate drug choice for intraperitoneal and bidirectional chemotherapy is essential, randomized clinical trials to determine the most optimal drug or drug combination are lacking, and only eight retrospective comparative clinical studies are available. Further clinical pharmacological studies are required to determine the most effective drug regimen for intraperitoneal and bidirectional chemotherapy in various indications. In the future, reliable drug sensitivity testing and genetic profiling of peritoneal metastases will be needed for enabling patient-specific therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgical Oncology, Medical School of Crete University Hospital, Heraklion, Greece.
Zitieren
APA
de Bree, E., Michelakis, D., Stamatiou, D., Romanos, J., & Zoras, O. (2017). Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura and Peritoneum, 2(2), 47-62. https://doi.org/10.1515/pp-2017-0010
Vancouver
de Bree E, Michelakis D, Stamatiou D, Romanos J, Zoras O. Pharmacological principles of intraperitoneal and bidirectional chemotherapy. Pleura and Peritoneum. 2017;2(2):47-62. doi:10.1515/pp-2017-0010
BibTeX
@article{deBree2017,
author = {de Bree, Eelco and Michelakis, Dimosthenis and Stamatiou, Dimitris and Romanos, John and Zoras, Odysseas},
title = {Pharmacological principles of intraperitoneal and bidirectional chemotherapy},
journal = {Pleura and Peritoneum},
year = {2017},
volume = {2},
number = {2},
pages = {47--62},
doi = {10.1515/pp-2017-0010}
}
EUVIMED